LAG-3 (mouse):Fc (mouse), (recombinant)
[Lymphocyte activation gene 3, FDC protein, CD223]
| ALX-522-099-C050 | 50 µg | 434.00 USD |  |
|
| ALX-522-099-C500 | 500 µg | 1'625.00 USD | |
|
Product Specification
| Concentration: | 0.5mg/ml |
| Endotoxin Content: | <1EU/µg purified protein (LAL test; Bio Whittaker). |
| MW: | ~180kDa (SPS-PAGE, nonreducing), ~80kDa (SPS-PAGE, reducing) |
| Purity: | ≥95% (SDS-PAGE) |
| Formulation: | Liquid. In PBS. |
| Biological Activity: | Induces maturation of mouse dendritic cells in vitro. Induces CD4 and CD8 antigen-specific T cells responses when coinjected s.c. in mice, together with the antigen. |
| Source/Host: | Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of mouse LAG-3 (D1-D4) is fused to the Fc portion of mouse IgG2a (hinge-CH2-CH3). |
| Reconstitution: | Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| Specificity: | Binds to human and mouse MHC class II. |
| Application: | Flow Cytometry |
| Shipping: | SHIPPED ON BLUE ICE |
| Long Term Storage: | +4°C |
| Use/Stability: | Stable for at least 6 months after receipt when stored at +4°C. |
| Miscellaneous/General: | The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4 [1]. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa) [1,2]. The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome [3]. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses [4]. |
| Background / Technical Information: | Swiss Prot link Q61790: Lymphocyte activation gene-3 protein (mouse) (Precursor) |
Product Literature References
LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice: P. Cappello, et al.; Cancer Res. 63, 2518 (2003), Abstract; Full Text
General Literature References
Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production F. Annunziato, et al. FASEB J. 10 769 (1996) Abstract
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo C. Lienhardt, et al. Eur. J. Immunol. 32 1605 (2002) Abstract
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination F. Triebel Trends Immunol. 24 619 (2003) Abstract
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors F. Triebel, et al. Cancer Lett. 235 147 (2006) Abstract
Product Toolbox
PRODUCT RESOURCES
Datasheet
RELATED PRODUCTS
By catalog section:
PRODUCT SUPPORT
Technical ServiceBulk Quantity Quote
Customer Service
